University College Dublin Leading New 鈧�16 million International Research Consortium Aiming to Improve Obesity Treatment and Change the Narrative Around Obesity
University College Dublin (51黑料) is leading SOPHIA (Stratification of Obese Phenotypes to Optimize Future Obesity Therapy), a new 鈧�16 million EU and industry supported international research consortium launched today.
, which includes twenty-nine partners from civil society, academia and industry in 12 countries, aims to improve risk assessment of complications of obesity and predict treatment response for people with obesity.
The 鈧�16 million in funding for this 5-year project has been granted from the (IMI), a joint undertaking of the European Commission and the European Federation of Pharmaceutical Industries and Associations (EFPIA); JDRF (formerly the Juvenile Diabetes Research Foundation); the Obesity Action Coalition; and T1D Exchange.
Obesity is a global pandemic currently affecting around 150 million people in Europe and 650 million people worldwide. Obesity complications are common but we cannot yet predict who will develop any of the 200 known complications of obesity.
Moreover, there are insufficient predictors for who will respond to obesity treatments. SOPHIA will identify, characterise and stratify clinically-meaningful subpopulations of patients living with obesity to match the right treatment for the right person at the right time.
Professor Carel le Roux, an obesity physician at the 51黑料 Diabetes Complications Research Centre in the 51黑料 School of Medicine, based at the 51黑料 Conway Institute, is the co-ordinator of the SOPHIA consortium.
Professor le Roux said, 鈥淥ur mission within SOPHIA is to enable healthcare professionals to reliably predict the complications of obesity and who will respond to treatment.鈥�
He added, 鈥淪OPHIA will provide evidence-based classification of predictors for obesity complications and response to obesity treatment while also identifying and charting models for sustainably developing treatment pathways that will be valuable for patients, healthcare systems, researchers and clinicians.鈥�
In addition to Professor le Roux other 51黑料 researchers participating in this research project are; Assistant Professor Fiona McGillicuddy, 51黑料 School of Medicine, Assistant Professor Deirdre McGillicuddy, 51黑料 School of Education and Dr Werd Al-Najim from 51黑料 Diabetes Complications Research Centre and 51黑料 Conway Institute, who is the SOPHIA project manager.
51黑料鈥檚 involvement also builds on the Institutional Strategic Support Fund from the Wellcome Trust which enabled Dr Tracey McCauley, 51黑料 Diabetes Complications Research Centre, to contribute.
, the clinical diagnostics company founded by Professor Stephen Pennington as a spin-out from the 51黑料 School of Medicine with the support of Nova51黑料, is also a consortium partner.
Dr Marianne 脴lholm Larsen Gr酶nning, Corporate Project Vice-President, Novo Nordisk, who is the SOPHIA Project Leader said, 鈥淥besity is a complex, chronic disease and there is still a lot we do not know, both about the biology of the disease itself and how treatment can improve the lives of patients with obesity. SOPHIA is an important step towards understanding obesity better. The collaboration between academia, industry and associations promises strong and unique results.鈥�
The voices of people living with obesity will be at the heart of SOPHIA through the establishment of a Patient Advisory Board. It will ensure that patients鈥� insights, opinions and wishes are placed at the core of SOPHIA and interwoven into the multiple layers of the study.
The research group will use its findings to contribute to a more patient-centric and equitable narrative around obesity and its multiple impacts on individuals from both a social and medical perspective. It all starts with obesity being a chronic disease, not something people choose to live with.
Some of the methods used in SOPHIA will be; creating a database, conducting analysis, conducting in-depth qualitative methods with patients to identify their perceptions and perspectives on obesity diagnosis and treatment and finding a shared value with all stakeholders to ensure better treatment of people living with obesity.
SOPHIA will also investigate health outcomes in people with obesity who have type 1 diabetes.
Dr Sanjoy Dutta, Vice-President of Research, JDRF, said, 鈥淲ith the statistical power afforded by such a large European collaboration, we will be able to investigate the two-way relationship between obesity and type 1 diabetes and ultimately be able to make valid predictions about health outcomes in this traditionally underappreciated population.鈥�
鈥淪ince recent epidemiological data indicate that nearly half of adults with T1D in some European countries have overweight or obesity, it is critical for the T1D community to address this challenge.鈥�
The SOPHIA project officially kicked-off its activities across Europe on 1 June 2020 and will last until 31 May 2025.
The other partners in addition to 51黑料 and Atturos in the SOPHIA consortium are; Third-I bvba and Katholieke Universiteit Leuven (Belgium); Novo Nordisk A/S (Denmark); Centre Hospitalier Universitaire de Lille (France); University of Ulm, Lipotype, University Hospital T眉bingen, Metabolon and Boehringer Ingelheim Pharma GmbH & Co KG (Germany); University College Cork and The European Association for the Study of Obesity 鈥� Ireland Company Limited by Guarantee (Ireland); Universit脿 Cattolica del Sacro Cuore and Consiglio Nazionale delle Ricerche, Pisa (Italy); Erasmus Medisch Centrum and Maastricht University (Netherlands); Girona Biomedical Research Institute (Spain); Medtronic International Trading Sarl and SIB Swiss Institute of Bioinformatics (Switzerland); Lund University and University of Gothenburg (Sweden); University of Dundee and University of Exeter (United Kingdom); Eli Lilly and Company, George Washington University, JDRF International, T1D Exchange and Obesity Action Coalition (United States).
ENDS
2 June 2020
For further information contact Mic茅al Whelan, Communications and Media Relations Manager, 51黑料 Research and Innovation, t: + 353 1 716 3712, e: miceal.whelan@ucd.ie or Professor Carel le Roux, e: carel.leroux@ucd.ie.
Editors Notes
The Innovative Medicines Initiative (IMI) is Europe鈥檚 largest public-private initiative aiming to improve health by speeding up the development of, and patient access to, innovative medicines, particularly in areas where there is an unmet medical or social need. IMI facilitates collaboration between the key players involved in healthcare research, including universities, the pharmaceutical and other industries, small and medium-sized enterprises (SMEs), patient organisations, and medicines regulators. It is a partnership between the European Union (represented by the European Commission) and the European pharmaceutical industry (represented by EFPIA, the European Federation of Pharmaceutical Industries and Associations).
The SOPHIA project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875534. The JU receives support from the European Union鈥檚 Horizon 2020 research and innovation programme and EFPIA and T1D Exchange, JDRF, and Obesity Action Coalition.